Powered by

Exicure to Present at TIDES 2019 on Preclinical and Clinical Development of AST-008

May 22, 2019 - Business Wire
Event Announcements

Exicure, Inc. (OTCQB: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA(TM)) constructs, announced a presentation at TIDES: Oligonucleotide and Peptide Therapeutics, the world's largest meeting to accelerate oligonucleotide and peptide products from early discovery to late-stage development and commercialization.

The talk, "Preclinical and Clinical Development of AST-008, A Toll-like Receptor Agonist 9 Spherical Nucleic Acid for Immuno-...